Please login to the form below

Not currently logged in
Email:
Password:

Celgene engages IBM Watson for patient safety work

Aims to improve its pharmacovigilance methods with a new cloud-based platform
Celgene

Celgene has teamed up with IBM Watson Health to improve its existing pharmacovigilance methods through the creation of a new cloud-based drug evaluation platform.

Built using the Watson Health Cloud supercomputer, the new system will collect patient data to assess, monitor and report adverse drug reactions.

IBM says the high volumes of data will be obtained from “diverse sources, including anonymised electronic medical records, medical claims databases and other healthcare information sources”.

'Watson for Patient Safety' aims to aid life sciences companies in managing and interpreting Individual Case Safety Reports (ICSRs), using its trademark cognitive computing technology to increasingly identify potential drug safety signals.

The partners hope this will reduce the time and monetary drain of failed late-stage clinical trials for drug developers through access to such comprehensive outcome- and evidence-based profiling, ultimately getting drugs to market faster.

John Freeman, Celgene's corporate vice president of global drug safety and risk management, said: “With this collaboration, we intend to create a paradigm shift in identifying patient safety data that we hope can be applied across the entire product lifecycle - from early development to approved medicines.

“The new offering we are co-developing will bring the cognitive computing power of Watson and its growing view of clinical, research and social health data to bear on this critical healthcare challenge.”

Due to be developed across several phases, the first module of 'Watson for Patient Safety' is expected to be ready within the next year.

Article by
Rebecca Clifford

3rd November 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....